BCLI

Brainstorm Cell Therapeutics Inc.

Price

$0.83

return (12m)

27.85%

p/e

-0.82

p/bv

-0.74

DIVIDEND YIELD

0.00%

BCLI price

Brainstorm Cell

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*The amount considers the reinvestment of dividends.

Return on Investment BCLI

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

-5.57%

3 months

-9.67%

1 year

27.85%

2 years

-63.07%

5 years

-98.23%

10 years

-97.47%

Profitability Comparator

If you had invested

years ago

ago, you would now have:

Fundamentals BCLI

Valuation

P/E

-0.82

Sector -3.10

Industry -3.10

P/BV

-0.74

Sector 1.77

Industry 1.77

P/Revenue (PSR)

Sector 2.01

Industry 2.01

EV/EBITDA

-2.40

Sector -216.68

Industry -216.68

EV/EBIT

-2.37

Sector -46.14

Industry -46.14

P/EBITDA

-0.88

Sector -21.54

Industry -21.54

P/EBIT

-0.86

Sector -27.94

Industry -27.94

P/Total Assets

10.86

Sector 1.05

Industry 1.05

P/Net Current Assets

-0.71

Sector -9.24

Industry -9.24

P/Working Capital

-0.71

Sector -135.45

Industry -135.45

EPS

-0.96

Sector -1.78

Industry -1.78

BVPS

-1.05

Sector 1.99

Industry 1.99

Efficiency

Gross Margin

0.00%

Sector 41.24%

Industry 41.24%

EBITDA Margin

Sector -17,192.92%

Industry -17,192.92%

EBIT Margin

0.00%

Sector -35.37%

Industry -35.37%

Net Profit Margins

0.00%

Sector -35.81%

Industry -35.81%

Asset Turnover

0.00

Sector 0.03

Industry 0.03

Profitability

ROE

90.69%

Sector -57.47%

Industry -57.47%

ROA

-1,331.65%

Sector -59.48%

Industry -59.48%

ROIC

-303.65%

Sector -2,385.22%

Industry -2,385.22%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

Sector -

Industry -

Debt

Current Ratio

0.03

Sector 2.92

Industry 2.92

Net Debt / EBITDA

0.01

Sector -21.38

Industry -21.38

Net Debt / EBIT

0.01

Sector -8.29

Industry -8.29

Net Debt / Equity

0.00

Sector -33,113.00

Industry -33,113.00

Gross Debt / Equity

0.00

Sector -0.84

Industry -0.84

Equity/Assets

-14.68

Sector 0.46

Industry 0.46

Liabilities/Assets

15.67

Sector 0.41

Industry 0.41

Growth

5Y Revenue CAGR

0.00%

Sector -

Industry -

5Y Earnings CAGR

-15.53%

Sector -

Industry -

Fundamentals BCLI

DRAG THE FRAME TO SEE MORE DATA

Assets	Price ($)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
BCLI Brainstorm Cell Therapeutics Inc.	$0.83	27.85%	0.00%	-0.82	-0.74	90.69%	0.00%
PFE Pfizer Inc.	$29.30	29.93%	5.91%	38.29	1.94	5.07%	6.80%
ABBV AbbVie Inc.	$283.02	27.22%	2.40%	79.71	-84.84	-106.44%	9.81%
NVO Novo Nordisk A/S	$38.44	-25.78%	4.74%	9.57	5.08	53.11%	35.32%
MRK Merck & Co. Inc.	$144.69	75.65%	2.34%	113.15	8.55	7.56%	4.77%
AZN AstraZeneca PLC	$165.06	-0.87%	1.95%	19.76	5.09	25.77%	16.95%
BMY Bristol-Myers Squibb Company	$58.66	42.28%	4.19%	13.18	5.48	41.59%	18.87%
ZTS Zoetis Inc.	$79.45	-43.79%	2.64%	12.52	10.49	83.77%	27.69%
AMGN Amgen Inc.	$426.52	46.68%	2.29%	26.86	20.10	74.80%	22.95%
REGN Regeneron Pharmaceuticals Inc.	$782.52	35.91%	0.47%	18.88	2.58	13.65%	27.86%
HALO Halozyme Therapeutics Inc.	$122.82	83.23%	0.00%	34.40	99.12	288.13%	24.86%
MCK McKesson Corporation	$994.67	27.04%	0.34%	25.91	-30.79	-118.84%	1.12%
VRTX Vertex Pharmaceuticals Incorporated	$502.58	20.58%	0.00%	29.00	6.31	21.76%	35.00%
CAH Cardinal Health Inc.	$250.05	61.38%	0.81%	34.89	-21.95	-62.92%	0.67%
ARGX argenx SE	$820.58	-2.74%	0.00%	13.83	3.67	26.52%	25.54%
HRMY Harmony Biosciences Holdings Inc.	$37.50	44.79%	0.00%	12.22	2.22	18.14%	18.88%
BIIB Biogen Inc.	$232.87	62.85%	0.00%	41.65	1.84	4.43%	8.32%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

BCLI - Historical Dividends

no dividend paid in the period.

Current Dividend Yield

0.00%

5-year average Dividend Yield

0.00%

Current Payout

—

5-year average Payout

—

ABOUT Brainstorm Cell

Brainstorm Cell Therapeutics Inc.

Average Investor10 user rating

4.0 (2 people)

United States

26 years

Founded: 2000

2003

Time since IPO - 23 years

40

Employees

Brainstorm Cell Therapeutics Inc. (United States) is listed on the Nasdaq and has a market capitalization of $8.58 million, with shareholders equity totaling $-11.60 million.

The company employs approximately 40 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Brainstorm Cell Therapeutics Inc. reported $- in revenue, generating net income of $-10.52 million.

Key financial metrics include a P/E ratio of -0.82, a price-to-book (P/B) ratio of -0.74, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker BCLI.

Market cap

$8.58 million

Net worth

$-11.60 million

$-11,600,000.00

Assets

$790.00 Thousand

$790,000.00

Total Shares Outstanding

11.00 million

11,000,000

Average Daily Trading Volume

$23.47 Thousand

$23,465.82

Sector

Health Care

Industry

Biotechnology

BCLI

BCLI revenue and profits

Financial Results BCLI

DRAG THE FRAME TO SEE MORE DATA

BCLI cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$994.67 27,04% (12M)

P/E

25.91

0.34%

ROE

-118.84%

P/BV

-30.79

CAH - Cardinal Health

$250.05 61,38% (12M)

P/E

34.89

0.81%

ROE

-62.92%

P/BV

-21.95

ABBV - AbbVie

$283.02 27,22% (12M)

P/E

79.71

2.40%

ROE

-106.44%

P/BV

-84.84

MRK - Merck & Co.

$144.69 75,65% (12M)

P/E

113.15

2.34%

ROE

7.56%

P/BV

8.55

AZN - AstraZeneca

$165.06 0,10% (12M)

P/E

19.76

1.95%

ROE

25.77%

P/BV

5.09

PFE - Pfizer

$29.30 29,93% (12M)

P/E

38.29

5.91%

ROE

5.07%

P/BV

1.94

BMY - Bristol-Myers Squibb

$58.66 42,28% (12M)

P/E

13.18

4.19%

ROE

41.59%

P/BV

5.48

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$994.67 27,04% (12 M)

P/L

25.91

0.34%

ROE

-118.84%

P/VP

-30.79

CAH - Cardinal Health

$250.05 61,38% (12 M)

P/L

34.89

0.81%

ROE

-62.92%

P/VP

-21.95

ABBV - AbbVie

$283.02 27,22% (12 M)

P/L

79.71

2.40%

ROE

-106.44%

P/VP

-84.84

MRK - Merck & Co.

$144.69 75,65% (12 M)

P/L

113.15

2.34%

ROE

7.56%

P/VP

8.55

AZN - AstraZeneca

$165.06 0,10% (12 M)

P/L

19.76

1.95%

ROE

25.77%

P/VP

5.09

PFE - Pfizer

$29.30 29,93% (12 M)

P/L

38.29

5.91%

ROE

5.07%

P/VP

1.94

BMY - Bristol-Myers Squibb

$58.66 42,28% (12 M)

P/L

13.18

4.19%

ROE

41.59%

P/VP

5.48

Frequently Asked Questions

What is the price of Brainstorm Cell (BCLI) today?

The current price of Brainstorm Cell (BCLI) is $0.83. The stock began the year trading around $0.56 and is currently priced at $0.83. You can follow the real-time price chart, review historical performance, and track broader market trends directly on the platform.

When does Brainstorm Cell (BCLI) pay dividends?

Brainstorm Cell (BCLI) did not pay dividends over the past year.

Is Brainstorm Cell (BCLI) a good investment?

Brainstorm Cell (BCLI) is currently trading at $0.83 with a P/E ratio of -0.82. This represents a -108% premium compared to its historical average P/E. Over the past year, the stock paid $0.00 in dividends, resulting in a dividend yield of 0.00%. The total shareholder return over the same period was 27.85%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Brainstorm Cell (BCLI) stock?

You can buy Brainstorm Cell (BCLI) shares through any brokerage account that provides access to U.S. stock exchanges. After opening and funding your account, simply search for the ticker symbol BCLI and place a buy order. Before investing, consider factors such as your financial goals, risk tolerance, and overall portfolio allocation.

How much would 100 shares of Brainstorm Cell (BCLI) yield today?

Over the past month, Brainstorm Cell (BCLI) has returned -5.57% — 27.85% over the past year, and -98.23% over the past five years, including price appreciation and dividends.

In the last 12 months, the company paid a total of 0.00 per share in dividends, resulting in a dividend yield of 0.00%.

If you were to purchase 100 shares of Brainstorm Cell (BCLI) today at the current price of $0.83 your total investment would be $83.10.

Based on historical performance, the investment would have grown to approximately:

$106.24 after 1 year
$1.47 after 5 years
$2.10 after 10 years

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

BCLI

Brainstorm Cell Therapeutics Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment BCLI

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

COMPARING BCLI WITH OTHER STOCK

ABOUT Brainstorm Cell

Brainstorm Cell Therapeutics Inc.

United States

26 years

2003

40

PROFIT X PRICE BCLI

Financial Results BCLI

BCLI cash flow

Asset, Revenue and Profit Growth - BCLI

BCLI balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BMY - Bristol-Myers Squibb

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BMY - Bristol-Myers Squibb

Frequently Asked Questions